Cargando…

A proteomic analysis of atrial fibrillation in a prospective longitudinal cohort (AGES-Reykjavik study)

AIMS: Atrial fibrillation (AF) is associated with high risk of comorbidities and mortality. Our aim was to examine causal and predictive relationships between 4137 serum proteins and incident AF in the prospective population-based Age, Gene/Environment Susceptibility-Reykjavik (AGES-Reykjavik) study...

Descripción completa

Detalles Bibliográficos
Autores principales: Jonmundsson, Thorarinn, Steindorsdottir, Anna E, Austin, Thomas R, Frick, Elisabet A, Axelsson, Gisli T, Launer, Lenore, Psaty, Bruce M, Loureiro, Joseph, Orth, Anthony P, Aspelund, Thor, Emilsson, Valur, Floyd, James S, Jennings, Lori, Gudnason, Vilmundur, Gudmundsdottir, Valborg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685397/
https://www.ncbi.nlm.nih.gov/pubmed/37967346
http://dx.doi.org/10.1093/europace/euad320
_version_ 1785151621897912320
author Jonmundsson, Thorarinn
Steindorsdottir, Anna E
Austin, Thomas R
Frick, Elisabet A
Axelsson, Gisli T
Launer, Lenore
Psaty, Bruce M
Loureiro, Joseph
Orth, Anthony P
Aspelund, Thor
Emilsson, Valur
Floyd, James S
Jennings, Lori
Gudnason, Vilmundur
Gudmundsdottir, Valborg
author_facet Jonmundsson, Thorarinn
Steindorsdottir, Anna E
Austin, Thomas R
Frick, Elisabet A
Axelsson, Gisli T
Launer, Lenore
Psaty, Bruce M
Loureiro, Joseph
Orth, Anthony P
Aspelund, Thor
Emilsson, Valur
Floyd, James S
Jennings, Lori
Gudnason, Vilmundur
Gudmundsdottir, Valborg
author_sort Jonmundsson, Thorarinn
collection PubMed
description AIMS: Atrial fibrillation (AF) is associated with high risk of comorbidities and mortality. Our aim was to examine causal and predictive relationships between 4137 serum proteins and incident AF in the prospective population-based Age, Gene/Environment Susceptibility-Reykjavik (AGES-Reykjavik) study. METHODS AND RESULTS: The study included 4765 participants, of whom 1172 developed AF. Cox proportional hazards regression models were fitted for 4137 baseline protein measurements adjusting for known risk factors. Protein associations were tested for replication in the Cardiovascular Health Study (CHS). Causal relationships were examined in a bidirectional, two-sample Mendelian randomization analysis. The time-dependent area under the receiver operating characteristic curve (AUC)-statistic was examined as protein levels and an AF-polygenic risk score (PRS) were added to clinical risk models. The proteomic signature of incident AF consisted of 76 proteins, of which 63 (83%) were novel and 29 (38%) were replicated in CHS. The signature included both N-terminal prohormone of brain natriuretic peptide (NT-proBNP)-dependent (e.g. CHST15, ATP1B1, and SVEP1) and independent components (e.g. ASPN, AKR1B, and LAMA1/LAMB1/LAMC1). Nine causal candidates were identified (TAGLN, WARS, CHST15, CHMP3, COL15A1, DUSP13, MANBA, QSOX2, and SRL). The reverse causal analysis suggested that most AF-associated proteins were affected by the genetic liability to AF. N-terminal prohormone of brain natriuretic peptide improved the prediction of incident AF events close to baseline with further improvements gained by the AF-PRS at all time points. CONCLUSION: The AF proteomic signature includes biologically relevant proteins, some of which may be causal. It mainly reflects an NT-proBNP-dependent consequence of the genetic liability to AF. N-terminal prohormone of brain natriuretic peptide is a promising marker for incident AF in the short term, but risk assessment incorporating a PRS may improve long-term risk assessment.
format Online
Article
Text
id pubmed-10685397
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-106853972023-11-30 A proteomic analysis of atrial fibrillation in a prospective longitudinal cohort (AGES-Reykjavik study) Jonmundsson, Thorarinn Steindorsdottir, Anna E Austin, Thomas R Frick, Elisabet A Axelsson, Gisli T Launer, Lenore Psaty, Bruce M Loureiro, Joseph Orth, Anthony P Aspelund, Thor Emilsson, Valur Floyd, James S Jennings, Lori Gudnason, Vilmundur Gudmundsdottir, Valborg Europace Translational Research AIMS: Atrial fibrillation (AF) is associated with high risk of comorbidities and mortality. Our aim was to examine causal and predictive relationships between 4137 serum proteins and incident AF in the prospective population-based Age, Gene/Environment Susceptibility-Reykjavik (AGES-Reykjavik) study. METHODS AND RESULTS: The study included 4765 participants, of whom 1172 developed AF. Cox proportional hazards regression models were fitted for 4137 baseline protein measurements adjusting for known risk factors. Protein associations were tested for replication in the Cardiovascular Health Study (CHS). Causal relationships were examined in a bidirectional, two-sample Mendelian randomization analysis. The time-dependent area under the receiver operating characteristic curve (AUC)-statistic was examined as protein levels and an AF-polygenic risk score (PRS) were added to clinical risk models. The proteomic signature of incident AF consisted of 76 proteins, of which 63 (83%) were novel and 29 (38%) were replicated in CHS. The signature included both N-terminal prohormone of brain natriuretic peptide (NT-proBNP)-dependent (e.g. CHST15, ATP1B1, and SVEP1) and independent components (e.g. ASPN, AKR1B, and LAMA1/LAMB1/LAMC1). Nine causal candidates were identified (TAGLN, WARS, CHST15, CHMP3, COL15A1, DUSP13, MANBA, QSOX2, and SRL). The reverse causal analysis suggested that most AF-associated proteins were affected by the genetic liability to AF. N-terminal prohormone of brain natriuretic peptide improved the prediction of incident AF events close to baseline with further improvements gained by the AF-PRS at all time points. CONCLUSION: The AF proteomic signature includes biologically relevant proteins, some of which may be causal. It mainly reflects an NT-proBNP-dependent consequence of the genetic liability to AF. N-terminal prohormone of brain natriuretic peptide is a promising marker for incident AF in the short term, but risk assessment incorporating a PRS may improve long-term risk assessment. Oxford University Press 2023-11-15 /pmc/articles/PMC10685397/ /pubmed/37967346 http://dx.doi.org/10.1093/europace/euad320 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Translational Research
Jonmundsson, Thorarinn
Steindorsdottir, Anna E
Austin, Thomas R
Frick, Elisabet A
Axelsson, Gisli T
Launer, Lenore
Psaty, Bruce M
Loureiro, Joseph
Orth, Anthony P
Aspelund, Thor
Emilsson, Valur
Floyd, James S
Jennings, Lori
Gudnason, Vilmundur
Gudmundsdottir, Valborg
A proteomic analysis of atrial fibrillation in a prospective longitudinal cohort (AGES-Reykjavik study)
title A proteomic analysis of atrial fibrillation in a prospective longitudinal cohort (AGES-Reykjavik study)
title_full A proteomic analysis of atrial fibrillation in a prospective longitudinal cohort (AGES-Reykjavik study)
title_fullStr A proteomic analysis of atrial fibrillation in a prospective longitudinal cohort (AGES-Reykjavik study)
title_full_unstemmed A proteomic analysis of atrial fibrillation in a prospective longitudinal cohort (AGES-Reykjavik study)
title_short A proteomic analysis of atrial fibrillation in a prospective longitudinal cohort (AGES-Reykjavik study)
title_sort proteomic analysis of atrial fibrillation in a prospective longitudinal cohort (ages-reykjavik study)
topic Translational Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685397/
https://www.ncbi.nlm.nih.gov/pubmed/37967346
http://dx.doi.org/10.1093/europace/euad320
work_keys_str_mv AT jonmundssonthorarinn aproteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy
AT steindorsdottirannae aproteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy
AT austinthomasr aproteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy
AT frickelisabeta aproteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy
AT axelssongislit aproteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy
AT launerlenore aproteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy
AT psatybrucem aproteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy
AT loureirojoseph aproteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy
AT orthanthonyp aproteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy
AT aspelundthor aproteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy
AT emilssonvalur aproteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy
AT floydjamess aproteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy
AT jenningslori aproteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy
AT gudnasonvilmundur aproteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy
AT gudmundsdottirvalborg aproteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy
AT jonmundssonthorarinn proteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy
AT steindorsdottirannae proteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy
AT austinthomasr proteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy
AT frickelisabeta proteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy
AT axelssongislit proteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy
AT launerlenore proteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy
AT psatybrucem proteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy
AT loureirojoseph proteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy
AT orthanthonyp proteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy
AT aspelundthor proteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy
AT emilssonvalur proteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy
AT floydjamess proteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy
AT jenningslori proteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy
AT gudnasonvilmundur proteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy
AT gudmundsdottirvalborg proteomicanalysisofatrialfibrillationinaprospectivelongitudinalcohortagesreykjavikstudy